Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -76.82% is 24% above its 5-year average of -101.46%, near the high end of its 5-year range (-902.85%–-37.54%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.76% above its 12-month average of -90.12%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -76.82%.
RETURN ON EQUITY (ROE)
-76.82%
RETURN ON EQUITY (ROE) AVG TTM
-90.12%
RETURN ON EQUITY (ROE) AVG 3Y
-278.80%
RETURN ON EQUITY (ROE) AVG 5Y
-101.46%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.76%
CURRENT VS 3Y AVG
+72.44%
CURRENT VS 5Y AVG
+24.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-82.87%
vs the sector median at left
Rani Therapeutics Holdings, Inc.
Market Cap
$54.14M
Return on Equity (ROE)
-76.82%
TTM Avg
-90.12%
3Y Avg
-278.80%
5Y Avg
-101.46%
Market Cap
$53.70M
Return on Equity (ROE)
-36114.03%
TTM Avg
-31.09%
3Y Avg
-15.54%
5Y Avg
-12.44%
Market Cap
$55.25M
Return on Equity (ROE)
-60.85%
TTM Avg
-77.57%
3Y Avg
-56.89%
5Y Avg
-53.13%
Market Cap
$52.83M
Return on Equity (ROE)
N/A
TTM Avg
171.70%
3Y Avg
384.85%
5Y Avg
251.73%
Market Cap
$52.60M
Return on Equity (ROE)
-27.93%
TTM Avg
-11.97%
3Y Avg
0.83%
5Y Avg
3.58%
Market Cap
$56.02M
Return on Equity (ROE)
-72.55%
TTM Avg
6.13%
3Y Avg
236.20%
5Y Avg
116.25%
Market Cap
$51.99M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$51.88M
Return on Equity (ROE)
-36.94%
TTM Avg
-31.55%
3Y Avg
-37.51%
5Y Avg
-20.44%
Market Cap
$57.01M
Return on Equity (ROE)
-132.16%
TTM Avg
-74.56%
3Y Avg
-71.32%
5Y Avg
22.85%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | $54.14M | -76.82% | -90.12% | -278.80% | -101.46% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | -36114.03% | -31.09% | -15.54% | -12.44% |
| Aldeyra The (ALDX)vs › | $55.25M | -60.85% | -77.57% | -56.89% | -53.13% |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A | 171.70% | 384.85% | 251.73% |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | -27.93% | -11.97% | 0.83% | 3.58% |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | -72.55% | 6.13% | 236.20% | 116.25% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | 31.64% | 119.26% | -26.51% |
| ImageneBio Inc (IMA)vs › | $51.88M | -36.94% | -31.55% | -37.51% | -20.44% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | -132.16% | -74.56% | -71.32% | 22.85% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | -278.89% | -162.92% | 25.71% | 0.37% |
ROE
-76.8%
ROA
-49.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -76.82% |
| 2026-03-31 | -103.65% |
| 2025-12-31 | -89.89% |
| 2024-09-30 | -902.85% |
| 2024-03-31 | -447.16% |
| 2023-12-31 | -264.03% |
| 2023-09-30 | -203.14% |
| 2023-06-30 | -142.84% |
| 2023-03-31 | -106.56% |
| 2022-12-31 | -83.00% |
| 2022-09-30 | -63.97% |
| 2022-06-30 | -46.38% |
| 2022-03-31 | -37.54% |
| 2021-12-31 | -40.95% |
| 2021-09-30 | -60.21% |
